Now Playing
|Videos|April 14, 2023
How PSA Has Impacted the Use of ADT in Prostate Cancer
Tia Higano, MD, FACP, provides a historical perspective on prostate cancer the use of androgen-deprivation therapy (ADT) and on prostate-specific antigen (PSA) in diagnosis and monitoring.
Advertisement
Advertisement
Related to this article
“Cardiovascular assessment should begin when the patient is being selected for treatment, not after the toxicity emerges,” said Faisal Mehmud, MD, MRCP.
Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
3
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5